Kornimate/medical-research-clean huggingface dataset:
atherosclerosis and acute ischemic stroke study

Conditions: Atherosclerosis; Inflammation; Ischemic Stroke

Summary: a significant proportion of strokes are thromboembolic in nature, arising from atherosclerotic plaque at the carotid bifurcation. it is now wellknown that inflammation plays a key role in atherogenesis and plaque destabilization. however the identification and characterization of the different inflammatory factors, as well as their relative importance, have not been clarified. this main aim of this study is to identify new risk markers for atherosclerosis and to characterize more precise methods for detection of the unstable carotid plaque with increased stroke-risk.

this project include patients with asymptomatic and symptomatic carotid stenosis \>50%. patients with acute ischemic stroke will also be included with carotid artery stenosis \<50% (study 3). the patient group will undergo a clinical neurological examination, ultrasound of the neck-arteries and a blood sample. the majority will also have a ct-angiography of the neck arteries and a cerebral mri or ct. carotid plaques removed by surgery (carotid end-arterectomy) and thrombs removed by thrombectomy will undergo histological analyses. study 1: plasma markers will be analysed and compared to clinical symptoms, ultrasound assessment of the plaque, cerebral mri (or ct). study 2: results from advanced ultrasound of the carotid plaque including assessment of plaque morphology will be compared to histology of the removed plaque. plasma markers and clinic will be related to the findings. the correlation between the different diagnostic modalities and the histologic conclusion will be assessed. study 3: this study focus on plasma markers in an acute ischemic stroke due to a carotid plaque compared to an acute ischemic stroke with a cardial embolic source. thrombi removed from the cerebral artery by thrombectomy will undergo histological analysis and the results will be compared to plasma markers and stroke aetiology.

Eligibility criteria:
inclusion criteria: * all patients with an atherosclerotic carotid stenosis \>50% admitting one of the study centres as an in-patient or an out-patient will be considered for inclusion. * acute stroke patients treated with thrombectomy at oslo university hospital will be included even though the carotid stenosis is \< 50%. exclusion criteria: * malign disease * inflammatory disease
open study: pain management treatment needs interviews

Conditions: HIV; Peripheral Neuropathy

Summary: presently, there are few options for medically managing hiv-related painful peripheral sensory neuropathy (hiv-sn). psychological treatments, including cognitive behavioural therapy (cbt), represent a potentially viable addition to the treatment of painful hiv-sn. however, there is a scarcity of research on psychological treatment approaches for pain management in people with hiv. this study will use in-depth semi-structured interviews to examine the needs of people with painful hiv-sn for a psychologically-based pain management treatment that may be delivered over the internet. interview questions will examine participants' needs in terms of treatment content and delivery format. men and women, ethnic minorities, and people who use recreational drugs will be sampled to ensure that interview responses reflect the views of people most commonly suffering from this condition. approximately 30 people will be recruited for the study. the interviews will be audio recorded, transcribed verbatim, and coded to identify themes. the interview responses will be used to develop and tailor a version of cbt for people with painful hiv-sn. it is hoped that tailoring the treatment based on the qualitative interview responses will increase the acceptability of the treatment and will improve treatment adherence rates for a future study.

this report is independent research supported by the national institute for health research (nihr post doctoral fellowship, dr whitney scott, pdf-2015-08-059). the views expressed in this publication are those of the authors and not necessarily those of the nhs, the national institute for health research or the department of health.

Eligibility criteria:
inclusion criteria: * adults aged 18 years or older. * living with hiv. * a positive screen for peripheral sensory neuropathy, as indicated by: presence of self-reported bilateral foot pain and/or numbness in a symmetrical distribution. * positive screen for symptoms of neuropathic pain in the feet, as indicated by a score of greater than or equal to 3 on the patient reported outcomes section of the neuropathic pain interview. * pain in the feet present most days for at least 3 months. * average pain intensity of greater than or equal to 4/10. * average interference of pain with daily activities is greater than or equal to 4/10. exclusion criteria: * presence of excessive alcohol consumption, hypothyroidism, vitamin b12 deficiency, diabetes, exposure to isoniazid or chemotherapy drug treatment, or a known history of a neuropathy due to a cause other than hiv or antiretroviral treatment * unable to conduct interview in english. * current diagnosis of dementia or learning disability. * unwilling to provide written informed consent.

Keywords: hiv peripheral neuropathy chronic pain qualitative research
safety, feasibility and efficacy of sulforaphane (avmacol extra strength) in chronic kidney disease

Conditions: Chronic Kidney Disease Stage 3; Chronic Kidney Disease Stage 4

Summary: the sulforaphane production system® in avmacol extra strength (es) supplies broccoli seed extract (glucoraphanin) and myrosimax® (active myrosinase enzyme) which helps promote sulforaphane production in your body. the investigators hypothesize that daily intake of avmacol es can decrease kidney disease progression rate and decrease markers of oxidative stress and inflammation in chronic kidney disease (ckd) patients. they will test this hypothesis in a randomized, double-blind, placebo controlled phase 2 clinical trial. this proposed study has been funded by the national institute of diabetes and digestive and kidney diseases (niddk), r01 dk128677.

the investigators will test the safety and efficacy of avmacol es in chronic kidney disease (ckd) patients. after having established a safe dose of 4 tablets once daily in participants with ckd stages 3 - 4 in the pharmacokinetic (pk) phase, the investigators will enroll 100 participants from the kidney clinic at the university of rochester medical center and highland hospital with ckd stages 3 - 4 who will be randomized to avmacol es or placebo in a 1:1 ratio in a blinded manner.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years and ≤ 80 years * estimated glomerular filtration rate (egfr) ≥ 20 and \< 60 ml/min/1.73m2 and a decline in egfr of ≥ 3 ml/min/1.73m2 /year in the previous 12 ± 2 months * able to provide consent * able to swallow avmacol es or placebo capsules exclusion criteria: * significant co-morbid conditions with life expectancy of \< 1 year * serum potassium of \> 5.5 milliequivalents per liter (meq/l) at screening * new york heart association class 3 or 4 heart failure symptoms, known ejection fraction (ef) ≤ 30% or hospital admission for heart failure within the past 3 months * factors judged to limit adherence to interventions based on appointment attendance and medication treatment compliance; pi will make this determination * current participation in another medical intervention study * known to be pregnant or planning to become pregnant or currently breastfeeding; determined by self-report and medical record history. a urine pregnancy test will be completed for individuals of childbearing potential before administering the study drug, and repeated thereafter at every study visit (\~ every 3-4 months) * history of dementia documented in the medical record * on anticoagulants or immunosuppression * under treatment for cancer * delayed gastric emptying or similar gi conditions non-english-speaking individuals are excluded in this randomized phase of the study because the lack of english proficiency will affect a subject's ability to report problems or adverse events. if a patient cannot read, the consent form will be read to them by the research coordinator.
xarelto for real life anticoagulation in pulmonary embolism (pe) in china

Conditions: Pulmonary Embolism

Summary: einstein pe study demonstrated that rivaroxaban is at least as effective as the current standard therapy with 51% relative risk reduction of major bleeding (1.1% vs. 2.2%, hr 0.49, 95% ci, 0.31-0.79), in the treatment and secondary prevention of pe. however these patients were required to meet strict eligibility criteria. little is known about pe treatment in china in routine clinical practice and in a real world study patients at higher or lower risk for adverse events can possibly recruited. bayer conducts this study to yield post-authorization safety information in rivaroxaban under real-life conditions in china.


Eligibility criteria:
inclusion criteria: * female or male patients, who are at \>=18 years * diagnosis of acute symptomatic or asymptomatic pe, objectively confirmed * indication for anticoagulation therapy for at least 3 months (as assessed by the attending investigator) * willing to participate in this study, having given informed consent and willing to participate in the routine follow-up during the period of rivaroxaban treatment. exclusion criteria: * pre-treatment with any anticoagulant for the index pe more than the 2 weeks. * patients with another indication for anticoagulation other than vte. * patients who participated in another study within 30 days

Keywords: venous thromboembolism anticoagulation rivaroxaban observation study
bowel colonization with multi-drug resistant bacterial species in hospitalized patients with acute-on chronic liver failure (aclf), and its relationship with extra-intestinal infectious events and short-term outcomes.

Conditions: Acute-On-Chronic Liver Failure

Summary: bowel colonization with anti-microbial resistant bacteria increases the risk of clinical infections. infections caused by anti-microbial resistant bacteria have been associated with increased mortality, prolonged hospital stay, and increased costs. in addition, with the emergence of carbapenemase resistant bacterial species, there may not be any effective therapy for patients infected with such resistant species. bowel colonization with anti-microbial resistant bacteria is an established risk factor for infections due to resistant bacteria, especially in transplanted patients and in intensive care unit. in this study we will study whether bowel colonisation in acute on chronic liver failure patient increases the risk of infection development in extra intestinal sites.


Eligibility criteria:
inclusion criteria: - patients with acute on chronic liver failure admitted to the ward/high dependency unit/intensive care unit. exclusion criteria: 1. patients on immunosuppressant medications or on daily steroids (excluding inhaled steroids) or \>2 weeks. 2. patients with additional primary or acquired immunosuppressive states like hypogammaglobinemia, post-splenectomy, human immunodeficiency virus (hiv) infection etc. 3. neutropenia defined as absolute neutrophil count or total white blood cell count (wbc) \<500/mm3 4. patients with extra-hepatic malignancy or on cytotoxic chemotherapy. 5. patients with ileus, bowel hypomotility, severe constipation requiring laxatives/purgatives or enemas to evacuate. 6. patients with fresh or altered blood in stools. 7. patients with anatomical predisposition to infection/ bacterial seeing like prosthesis or foreign body. patients with exfoliative skin conditions, significant mucosal ulcerations, or skin ulcers. patients who have received \> 2 weeks of antibiotics before current admission. 8. pregnant patients.
the effectiveness of antimicrobial breathing system on the presence of multidrug-resistant organisms

Conditions: Bacterial Contamination

Summary: the aim of this study is to investigates the effectiveness of antimicrobial breathing system on multidrug-resistant organisms (mdro).

background: cross transmission via skin contact and environmental media is the main route for common outbreak of health care-associated infection which more likely to be improved or prevented by infection control program. silver knight uses silver ions to disrupt the normal enzymatic activities of bacteria for reducing microbial growth within, and on, the surface of the breathing systems. it functions as a safe, quick and effective catalyst to deactivate pathogenic bacteria and prevent their proliferation. however, there was no study comparing the standard ventilator circuit with silver knight. this study focuses on the effectiveness of antimicrobial breathing system in mdro which including carbapenem-resistant, vancomycin-resistant and multi-drug resistant. study design: this is a prospective, randomized study in a single hospital in the intensive care unit. methods: in this study, we conduct a cluster-randomized crossover, single-centre trial. there are two groups: 1. control group: standard ventilator circuit in odd number month. 2. experimental group: silver knight in even number month this study is expected to recruit 200 subjects. during this period, the ventilator circuits are all routinely used, only the tubing will not be discarded after use for specimen collection.and the mdro on the surfaces of ventilator circuits will be analyzed and evaluated. effect: we expect the antimicrobial breathing system could be more effectively than the standard ventilator circuit. the policy related to current ventilator circuit will be revised according to the results of this study. key words: antimicrobial breathing system, ventilator circuits, multidrug-resistant organisms (mdro)

Eligibility criteria:
inclusion criteria: * mechanical ventilators in medisive careunit (micu) exclusion criteria: * using ventilators for less than seven days

Keywords: bacterial contamination nosocomail infection bacterial detection rate
fecal microbial transplantation in severe alcoholic hepatitis

Conditions: Alcoholic Hepatitis

Summary: 1. a subtype of alcoholic hepatitis (ah), named severe alcoholic hepatitis (sah) is associated with high short-term mortality (j hepatol, 2019) 2. the only sah treatment option - corticosteroids (cs) - are often contraindicated or ineffective (stopah trial) 3. new treatment modalities for remaining patients are much needed 4. fecal microbial transplantation (fmt) is one of the promising therapies 5. investigators aimed to see if fmt improves survival in patients admitted with sah, not responding to-, or non-eligible for cs.

* fmt via upper gi tract is provided to cs non-responders (nr) or non-eligible (ne) adult patients hospitalized with sah (determined by the lille-model). * modified version of the sarin fmt protocol is used with microbiota material procured from unrelated healthy donors.

Eligibility criteria:
inclusion criteria: * consenting, adult * severe form of acute alcoholic hepatitis (sah) * non-responder to corticosteroids according to the lille model * patients with sah not eligible for corticosteroids based on their contraindications exclusion criteria: * active infection * presence of untreated large / high-risk / bleeding esophageal varices * too sick for any therapy / futility (chronic extrahepatic organ failures, no potential for recovery, etc) * malignancy except for hepatocellular carcinoma in milan criteria

Keywords: alcoholic hepatitis nonresponders fecal microbial transplantation
hinged versus conventional 8 plate for correction of genu valgum or varum

Conditions: Genu Valgum or Varum; Growth; Arrested, Bone; Epiphyseal Arrest, Lower Leg

Summary: to assess the therapeutic effect of hinged 8-figure plate by comparing with the traditional 8-figure plate through a randomized controlled clinical trial by assessing the differences between preoperative and postoperative data. the hypothesis is that the hinged 8 plate provides low complications that this treatment is as good as the traditional one.

angular deformities of the lower limb is major clinical problems encountered in pediatric orthopedics. deformities can be either valgus or varus and most commonly affect the knee joint, which may result in patella dislocation, gait instability and serious impact on the appearance and function of the lower limbs. biomechanical studies and gait analysis found that genu varus increased medial articular surface pressure of the knee, while genu valgus increased lateral articular surface pressure, and both of them are the risk factors for osteoarthritis. surgical treatment techniques include osteotomy and hemiepipysidesis. osteotomy surgery is the gold standard for severe angular deformity or epiphyseal closed patients, but it was associated with lots of complications, including osteofascial compartment syndrome, neurovascular injury, deep soft tissue infection, nonunion and requiring a long recovery time. while, for patients whose epiphyseal is not closed, the traditional 8 plate hemiepipysidesis has fewer complications. however, it showed some problems in clinical applications, such as steel plate or screw broken. the investigators designed a new hinged 8 plate, which has two arms and a built-in hinge. based on the previous studies, investigators designed the rotation of the two arms ranged from 155° to 170° to better fit the contour of the physis in all stages of angular correction. that automatic change can also disperse repeated stress on the surface of periosteum and perichondrium during walking. the plate had been tested on animal models that the use of the hinged plate and screw system may be a more reliable technique with minimal complications for correction of angular deformities of the lower limb.

Eligibility criteria:
inclusion criteria: 1. idiopathic genu valgus or varum 2. without any treatment 3. lower limb mechanical axis over the tibial plateau in the range of 1/2; 4. epiphyseal not yet closed, with more than 12 months of growth potential exclusion criteria: 1. physiological genu valgus or varum 2. epiphyseal have closed or no growth potential 3. pathological limb deformity(blount disease, inflammation,trauma) 4. other causes of lower limb angular deformity. 5. with surgical contraindications

Keywords: genu valgum or varum eight-plate epiphysis arrest hemiepiphysiodesis
pharmacokinetics and safety of bi 201335 in patients with mild to severe renal impairment

Conditions: Hepatitis C

Summary: the main objective of this study is to investigate the influence of mild, moderate and severe renal impairment on the pharmacokinetics and safety of bi 201335 in comparison to a control group with normal renal function after single dose of bi 201335.


Eligibility criteria:
inclusion criteria: male and female healthy subjects with normal renal function and subjects with impaired renal function in relatively good health exclusion criteria: any relevant deviation from healthy conditions for healthy volunteers or significant diseases other than renal impairment for the renal impaired subjects
a controlled study of quality of life and it's related factors among gynecological cancer survivors

Conditions: Cervical Cancer; Ovarian Cancer; Endometrial Cancer

Summary: to compare quality of life and it's related factors between gynecological cancer survivor and healthy controls.

this study used a cross-sectional design. by using the method of purposive sampling, the 70 gynecological cancer patients who had completed the active treatments for six months will be recruited from the oncology and gynecology clinics of a medical center in the northern taiwan area. the 70 healthy controls without any cancer will be recruited from clinic and from friends and colleagues. the instruments include "sample characteristics questionnaire," "short form-12 (sf-12)," "medical outcome study sleep scale (mos-sleep)," "beck depression inventory-ii (bdi)," "state-trait anxiety inventory (stai)," "sexual activity questionnaire (saq), and "the experiences in close relationships-revised (ecr-r)." the data will be analyzed by descriptive statistical analysis, independent t-test, anova, scheffe's test, pearson's correlation, and stepwise regression.

Eligibility criteria:
inclusion criteria: * been diagnosed as cervical cancer, ovarian cancer or endometrial cancer, and has completed six months after the relevant treatment. * 20-70 years old * agreed to participate in this study. exclusion criteria: * combined with other non-gynecologic cancer (cervical cancer, ovarian cancer or endometrial cancer) patients.

Keywords: gynecological cancer survivors quality of life
exopulse mollii suit, spasticity & tissue oxygenation

Conditions: Multiple Sclerosis

Summary: spasticity is a frequent and debilitating symptom in patients with multiple sclerosis (ms). sustained contractile activity, such as that observed in spastic muscles, could reduce the capillary density and induce important changes in the muscular microcirculation, leading to oxidative changes within the muscular tissue. such changes reflect altered aerobic metabolism and impaired mitochondrial function. the available therapeutic strategies for treating spasticity and related symptoms are usually faced with limited efficacy and numerous side effects. for these reasons, non-invasive stimulation techniques, namely transcutaneous stimulation by means of exopulse mollii suit, might be of help in this context.


Eligibility criteria:
inclusion criteria: * definite ms diagnosis according to the 2017 mcdonald criteria since at least one month. * age between 18 and 75 years. * ability to walk freely or with the need of support (expanded disability status scale score (edss) \< 7.5). * being free of relapses in the last three months. * being french speaker, able to understand verbal instructions, and affiliated to the national health insurance (sécurité sociale). * having spasticity with a score of at least 1+ on the mas. exclusion criteria: * being included in another research protocol during the study period. * inability to undergo medical monitor for the study purposes due to geographical or social reasons. * having a cardiac stimulator, a ventriculoperitoneal shunt, an intrathecal baclofen pump or other contraindications to using exopulse mollii suit. * being pregnant * having a change in their pharmacological therapy in the last three months. * suffering from other somatic or neuropsychiatric diagnoses (e.g., arrhythmias, uncontrolled epilepsy, diseases causing osteoarticular and muscular pain). * having a body mass index above 35 kg/m2 * in case of the introduction of a medical device other than exopulse mollii suit during the study period. * patients under juridical protection (" mesure de protection judiciare : tutelle, curatelle, sauvegarde de justice ") * prisoners.

Keywords: multiple sclerosis oxygenation muscles spasticity